Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.83 |
| ▸ | CA1 | P00915 | 4/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616998 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28237938 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1665997 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL28156543 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1668977 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL5090059 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL3859929 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL6119566 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL10706703 | 1.00 | CA2 (0.83) | CA2CA1MAPK1GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL22235759 | 0.98 | CA2 (0.80) | CA2CA1MAPK1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936144-B | JAK inhibitors | 廖细斌 | 2023-12-22 | — | — | CN | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-111936144-A | JAK inhibitors | 廖细斌 | 2020-11-13 | — | — | CN | claimed |
| CN-102365276-A | Substituted spiro-amide compounds | GRUENENTHAL GMBH | 2012-02-29 | — | — | CN | claimed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| CN-118234731-A | RAS inhibitors | 锐新医药公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118206550-A | SHP2 inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118103074-A | Cytotoxic targeting chimeras for CCR2 expressing cells | 葛兰素史克知识产权发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| CN-117715658-A | Method for inhibiting RAS | 锐新医药公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111886229-A | Herbicidal compounds | 先正达参股股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-109789066-A | Drug and make-up composition containing resorcinol derivatives | 西姆莱斯股份公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109641025-A | Medicine containing ginger root CO2 extract | 西姆莱斯股份公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562046-A | Cosmetic composition containing sclareolide | 西姆莱斯股份公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109475482-A | Drug | 西姆莱斯股份公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-107459473-B | A kind of methionine derivative corrosion inhibiter and its synthetic method for pickling iron and steel | 唐山学院 | 2019-02-01 | — | — | CN | disclosed |
| CN-102365276-A | Substituted spiro-amide compounds | GRUENENTHAL GMBH | 2012-02-29 | — | — | CN | disclosed |
| WO-2010151815-A2 | 3,9-DIAZASPIRO[5,5]UNDECANE AMIDES AND UREAS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CA2 2999/4885CA1 4151/4885MAPK1 1561/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CA2 2999/4885CA1 4151/4885MAPK1 1561/4885 |
| US-11952352-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CA2 3819/4885CA1 4685/4885MAPK1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.